FDA 483 - Bio-Technology General (Israel), Ltd. - March 16, 2023
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Bio-Technology General (Israel) Ltd (BTG) in Kiryat Malachi revealed significant deficiencies in their drug substance manufacturing. The firm experienced widespread microbial contamination, inadequate process controls for viral and microbial safety, and ineffective cleaning procedures. Additionally, issues were noted with facility design, equipment maintenance, documentation, investigations, and the effectiveness of corrective actions, indicating a lack of robust quality control.
ID · f1a4f9b5-347c-497b-bfae-618426631fa7